Sodium alginate, sodium bicarbonate, calcium carbonate.
Each 10 mL contains Sodium alginate 500 mg, Sodium bicarbonate 213 mg, Calcium carbonate 325 mg.
PHARMACOLOGY: Pharmacodynamics: BELCID GERD is a combination of two antacids (calcium carbonate and sodium bicarbonate) and an alginate.
On ingestion, it reacts rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and studies have shown that the raft interacts with and caps the acid pocket in the stomach, reducing esophageal acid exposure. The raft floats on the stomach contents effectively impeding gastro-esophageal reflux, for up to 4 hours, and protecting the esophagus from acid, pepsin and bile. In severe cases the raft itself may be refluxed into the esophagus, in preference to the stomach contents, and exert a demulcent effect. In addition, in vitro evidence has shown that the raft has a secondary action and is able to entrap bile and pepsin within its structure, further protecting the esophagus from these gastric components.
Calcium carbonate neutralizes gastric acid to provide fast relief from indigestion and heartburn. This effect is increased by the addition of sodium bicarbonate which also has a neutralizing action. The total neutralizing capacity of the product at the lowest dose of two tablets is approximately 10 mEqH+.
Pharmacokinetics: The mode of action of BELCID GERD is physical and does not depend on absorption into the systemic circulation.
Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the esophagus such as acid regurgitation, heartburn and indigestion, for example following meals or during pregnancy, and for symptoms of excess stomach acid (hyperacidity). Can also be used to treat the symptoms of gastro-esophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy.
Orally administration; shake well before using.
Adults and children 12 years and over: Two to four teaspoons (10-20 ml) each time 4 times a day, after meals and before bedtime.
Children under 12 years: Should be given only on medical device.
Elderly: No dose modifications necessary for this age group.
Hepatic Impairment: No dose modification necessary.
Renal Insufficiency: Caution if highly restricted salt diet (see PRECAUTIONS).
Missed doses: If forgot to take BELCID GERD, the patient can continue dosing on the usual day of administration. Do not take a double dose to make up for missed doses.
Symptoms: Symptoms are likely to be minor in acute overdose; some abdominal distension may be noticed. Milk-alkali syndrome has occurred in individuals taking large doses of calcium carbonate per day for prolonged periods.
Treatment: In the event of overdosage symptomatic treatment should be given.
Hypersensitivity to sodium alginate, sodium bicarbonate and calcium carbonate.
BELCID GERD contains 127.88 mg sodium per 1 sachet (10ml) dose, equivalent to 6.4% of the WHO recommended maximum daily intake for sodium.
The maximum daily dose of this product is equivalent to 51.15% of the WHO recommended maximum daily intake for sodium.
This product is considered high in sodium. This should be particularly taken into account for those on a low salt diet (e.g. in some cases of congestive heart failure and renal impairment).
Each 2 sachets (20 ml) dose contains 260 mg (6.5 mmol) of calcium. Care needs to be taken in treating patients with hypercalcemia, nephrocalcinosis and recurrent calcium containing renal calculi.
Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.
If symptoms persist, or treatment is required for more than 7 days continuously, medical advice should be sought.
As with other antacid products, taking this product can mask the symptoms of other more serious, underlying medical conditions.
Contains methylparaben and propylparaben which may cause allergic reactions (possibly delayed).
EFFECT ON ABILITY TO DRIVE AND USE MACHINE: This medicine does not affect ability to drive and use machine.
Pregnancy: Based on this and previous experience the medicinal product may be used during pregnancy, if clinically.
Breastfeeding: No effects of the active substances have been shown in breastfed newborns/infants of treated mothers. BELCID GERD can be used during breast-feeding.
Fertility: Clinical data do not suggest that this product has an effect on human fertility.
Immune System: anaphylactic reaction, anaphylactoid reaction and hypersensitivity reactions such as urticaria.
Metabolism and Nutritional Disorder: alkalosis, acid rebound, hypercalcemia and milk-alkali syndrome.
Respiratory System: bronchospasm.
Gastrointestinal System: Constipation.
Due to the presence of calcium and carbonates which act as an antacid, a time-interval of 2 hours should be considered between intake of this product and the administration of other medicinal products, especially H2-antihistaminics, tetracyclines, digoxin, fluoroquinolones, iron salts, thyroid hormones, ketoconazole, neuroleptics, thyroxine, penicillamine, beta-blockers (atenolol, metoprolol, propranolol), glucocorticoid, chloroquine, diphosphonates, and estramustine.
Do not store above 30°C. Do not refrigerate or freeze.
A02BX13 - alginic acid ; Belongs to the class of other drugs used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Belcid GERD oral susp
10 mL x 12 × 1's;150 mL x 1's
Sign Out
